Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 24.4%

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 8,396 shares, a decline of 24.4% from the December 31st total of 11,105 shares. Based on an average trading volume of 42,227 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the company’s stock are sold short. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 42,227 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, VivoSim Labs presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is currently owned by hedge funds and other institutional investors.

VivoSim Labs Stock Up 71.8%

VIVS traded up $1.22 during trading on Friday, hitting $2.92. 72,074,651 shares of the company’s stock were exchanged, compared to its average volume of 1,100,603. VivoSim Labs has a fifty-two week low of $1.41 and a fifty-two week high of $21.96. The stock has a market cap of $7.62 million, a P/E ratio of -0.66 and a beta of 1.18. The business’s 50 day moving average is $2.06 and its two-hundred day moving average is $2.36.

VivoSim Labs (NASDAQ:VIVS) last posted its earnings results on Thursday, November 6th. The company reported ($0.98) EPS for the quarter. VivoSim Labs had a negative return on equity of 28.83% and a negative net margin of 1,413.57%.The business had revenue of $0.03 million for the quarter.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.